Featured Research

from universities, journals, and other organizations

'Junk DNA' plays active role in cancer progression, researchers find

Date:
May 29, 2013
Source:
University of Nottingham
Summary:
Scientists have found that a genetic rogue element produced by sequences until recently considered ‘junk DNA’ could promote cancer progression.

Scientists at The University of Nottingham have found that a genetic rogue element produced by sequences until recently considered 'junk DNA' could promote cancer progression.

The researchers, led by Dr Cristina Tufarelli, in the School of Graduate Entry Medicine and Health Sciences, discovered that the presence of this faulty genetic element -- known as chimeric transcript LCT13 -- is associated with the switching off of a known tumour suppressor gene (known as TFPI-2) whose expression is required to prevent cancer invasion and metastasis.

Their findings, published online this month in the journal Nucleic Acid Research, suggest that LCT13 may be involved in switching off TFPI-2.

This faulty genetic element was previously identified by Dr Tufarelli's team as part of a group of chimeric transcripts which are produced by DNA sequences frequently regarded as 'junk DNA' called LINE-1 (L1).

The work reported now expands on the previous observation as it indicates that in addition to acting as potential diagnostic tools these rogue elements can play an active role in cancer.

Dr Tufarelli said: "This study has identified a novel way in which 'junk DNA' can interfere with the normal functioning of a cell. The next step will be to understand how these elements become switched on. This information will be important in the design of treatments aimed to prevent activation of these elements and cancer progression."

The work was initiated through funding by Cancer Research UK, the Royal Society, MRC and Breakthrough Breast Cancer.


Story Source:

The above story is based on materials provided by University of Nottingham. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. A. Cruickshanks, N. Vafadar-Isfahani, D. S. Dunican, A. Lee, D. Sproul, J. N. Lund, R. R. Meehan, C. Tufarelli. Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer. Nucleic Acids Research, 2013; DOI: 10.1093/nar/gkt438

Cite This Page:

University of Nottingham. "'Junk DNA' plays active role in cancer progression, researchers find." ScienceDaily. ScienceDaily, 29 May 2013. <www.sciencedaily.com/releases/2013/05/130529121023.htm>.
University of Nottingham. (2013, May 29). 'Junk DNA' plays active role in cancer progression, researchers find. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/05/130529121023.htm
University of Nottingham. "'Junk DNA' plays active role in cancer progression, researchers find." ScienceDaily. www.sciencedaily.com/releases/2013/05/130529121023.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins